1,610 results match your criteria Cardiovascular Diabetology[Journal]


Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis.

Cardiovasc Diabetol 2019 Apr 16;18(1):49. Epub 2019 Apr 16.

Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202, Krakow, Poland.

Background: Type 2 diabetes mellitus (T2DM) is associated with a hypercoagulable state and increased neutrophil extracellular traps formation (NETosis). We investigated predictors of NETosis and cell death markers in circulating blood and their association with a prothrombotic state in T2DM.

Methods: In a cross-sectional study involving 113 T2DM patients aged 63. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0850-0DOI Listing
April 2019
2 Reads

Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes.

Cardiovasc Diabetol 2019 Apr 16;18(1):50. Epub 2019 Apr 16.

Department of Endocrinology & Metabosim, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.

Background: To investigate the effect of visit-to-visit fasting plasma glucose (FPG) variability on the left cardiac structure and function in patients with type 2 diabetes mellitus (T2DM).

Methods: In this prospective cohort study, 455 T2DM patients were included and follow-up for a median of 4.7 years. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0854-9DOI Listing
April 2019
1 Read

Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies.

Cardiovasc Diabetol 2019 Apr 15;18(1):48. Epub 2019 Apr 15.

Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Objective: The importance of triglycerides (TG) level as a risk factor for cardiovascular diseases (CVD) has been extensively investigated in the general population; however, their relationship in patients with type 2 diabetes mellitus (T2DM) is uncertain. We aimed to assess the association of TG with CVD in T2DM individuals.

Research Design And Methods: We searched bibliographic databases for studies published until June 2018, reporting on the relationship between TG and CVD in T2DM people. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0851-zDOI Listing
April 2019
5.235 Impact Factor

Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.

Cardiovasc Diabetol 2019 Apr 8;18(1):47. Epub 2019 Apr 8.

Department of Cardiology, First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China.

Background: The cardiovascular (CV) safety in terms of heart failure among different classes of treatment remains largely unknown. We sought to assess the comparative effect of these agents on heart failure outcomes.

Methods: This study was registered in the International Prospective Register of Systematic Reviews (CRD 42016042063). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0853-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454617PMC
April 2019
1 Read

Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.

Cardiovasc Diabetol 2019 Apr 5;18(1):46. Epub 2019 Apr 5.

Department of Internal Medicine IV, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, University Hospital Tübingen, Otfried-Müller-Str.10, 72076, Tübingen, Germany.

Background: SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight. However, it is unclear which body compartments are reduced and to what extent.

Methods: In this longitudinal observational study, we analyzed the body composition of 27 outpatients with type 2 diabetes mellitus during the first week and up to 6 months after initiation of treatment with SGLT2-inhibitors (n = 18 empagliflozin, n = 9 dapagliflozin) using bioimpedance spectroscopy (BCM, Fresenius). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0852-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451223PMC
April 2019
4.015 Impact Factor

The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.

Cardiovasc Diabetol 2019 Apr 1;18(1):45. Epub 2019 Apr 1.

Department of Medicine, Mackay Medical College, No.46, Sec. 3, Zhongzheng Rd., Sanzhi Dist., New Taipei City, 25245, Taiwan.

Background: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that SGLT2i, empagliflozin can improve cardiac hemodynamics in non-diabetic hypertensive heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0849-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638PMC

Proteomic alterations of HDL in youth with type 1 diabetes and their associations with glycemic control: a case-control study.

Cardiovasc Diabetol 2019 Mar 28;18(1):43. Epub 2019 Mar 28.

Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA.

Background: Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in cholesterol content. Alteration of the HDL proteome can result in dysfunctional HDL particles with reduced ability to protect against cardiovascular disease (CVD). The objective of this study was to compare the HDL proteomes of youth with T1DM and healthy controls (HC) and to evaluate the influence of glycemic control on HDL protein composition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0846-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437869PMC
March 2019
1 Read

Cardiovascular events, diabetes and guidelines: the virtue of simplicity.

Cardiovasc Diabetol 2019 Mar 28;18(1):42. Epub 2019 Mar 28.

University del Salvador, Virrey Loreto 2111, C1426DXM, Buenos Aires, Argentina.

Cardiovascular (CV) events or their minor syndromes, as various forms of ischemia, are medical emergencies that do not allow enough time for a guiding anamnesis or proper clinical examination, and lead to relying on Treatment Guidelines, but in many situations it is appropriate to deviate from them. Pathological studies have associated 75% of coronary artery events with atherosclerotic plaque rupture; it is now known that rupture alone is not enough for obstruction or occlusion of the vessel lumen. Concomitant conditions are required for the clinical manifestation of cardiovascular disease, including prothrombogenic and dysfunctional endothelium, less fibrinolytic capacity to protect it, increased platelet activation, increased adrenergic tone, microcirculation vasoconstriction, and other countless factors that contribute to thrombus formation, causing ischemia or infarction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0844-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437845PMC

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.

Cardiovasc Diabetol 2019 Mar 29;18(1):44. Epub 2019 Mar 29.

Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Background: Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.

Methods: Our analysis comprising 58 patients with type 2 diabetes mellitus identifies factors triggering the improvement of arterial stiffness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0839-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440009PMC

Comparison of outcomes after carotid endarterectomy between type 2 diabetic and non-diabetic patients with significant carotid stenosis.

Cardiovasc Diabetol 2019 Mar 25;18(1):41. Epub 2019 Mar 25.

Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Asanbyeongwon-gil 86, Songpa-gu, Seoul, 05505, Republic of Korea.

Background: We aimed to compare early and late outcomes after carotid endarterectomy (CEA) between Korean type 2 diabetic and non-diabetic patients and to investigate the impact of diabetes on the overall incidence of cardiovascular events after CEA.

Methods: We retrospectively analyzed 675 CEAs, which were performed on 613 patients with significant carotid stenosis between January 2007 and December 2014. The CEAs were divided into a type 2 diabetes mellitus (DM) group (n = 265, 39. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0848-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432752PMC

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.

Cardiovasc Diabetol 2019 Mar 25;18(1):40. Epub 2019 Mar 25.

Diabetes and Cardiovascular Center, University of Missouri School of Medicine, Columbia, MO, USA.

Objective: Diabetic nephropathy (DN) is characterized by glomerular and tubulointerstitial injury, proteinuria and remodeling. Here we examined whether the combination of an inhibitor of neprilysin (sacubitril), a natriuretic peptide-degrading enzyme, and an angiotensin II type 1 receptor blocker (valsartan), suppresses renal injury in a pre-clinical model of early DN more effectively than valsartan monotherapy.

Methods: Sixty-four male Zucker Obese rats (ZO) at 16 weeks of age were distributed into 4 different groups: Group 1: saline control (ZOC); Group 2: sacubitril/valsartan (sac/val) (68 mg kg day; ZOSV); and Group 3: valsartan (val) (31 mg kg day; ZOV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0847-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432760PMC
March 2019
1 Read

Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype.

Cardiovasc Diabetol 2019 03 22;18(1):39. Epub 2019 Mar 22.

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Background: The efficacy of cell transplantation in heart failure is reportedly modest, but adjuvant drugs combined with cell therapy may improve this efficacy. Peroxisome proliferator-activated receptor (PPAR)γ, one of the hypoglycemic medicine for diabetes mellitus, reportedly enhances cytokine production in adipose tissue-derived regenerative cells (ADRCs). We hypothesized that combined administration of PPARγ agonists and ADRCs may enhance the paracrine effects of adiponectin (APN), leading to functional recovery in a chronic myocardial infarction (MI) model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0829-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431071PMC
March 2019
1 Read

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.

Cardiovasc Diabetol 2019 03 21;18(1):38. Epub 2019 Mar 21.

Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2, Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.

Background: Using a meta-analysis of randomized controlled trials (RCTs), this study aimed to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia.

Methods: A search was performed using the MEDLINE, Cochrane Controlled Trials Registry, and ClinicalTrials.gov databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0845-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429757PMC

Left ventricular concentric geometry predicts incident diabetes mellitus independent of established risk factors in the general population: the Copenhagen City Heart Study.

Cardiovasc Diabetol 2019 03 20;18(1):37. Epub 2019 Mar 20.

Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev & Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.

Background: Subtle impairments in left ventricular (LV) function and geometry are common findings in individuals with diabetes. However, whether these impairments precede the development of diabetes mellitus (DM) is not entirely clear.

Methods: Echocardiograms from 1710 individuals from the general population free of prevalent diabetes mellitus were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0842-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427881PMC
March 2019
2 Reads

Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study.

Cardiovasc Diabetol 2019 03 19;18(1):36. Epub 2019 Mar 19.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #10 63-ro, Yeongdeungpo-gu, Seoul, 07345, South Korea.

Background: Because weight control is a cornerstone of diabetes management, it is important to understand the relationship of weight change to risk of cardiovascular disease (CVD) among patients with type 2 diabetes mellitus (DM). We aimed to investigate whether changes in weight early after diagnosis influence the incidence of CVD and all-cause mortality in patients with type 2 DM.

Methods: Using nationally representative data from the Korean National Health Insurance System, 173,246 subjects with new-onset DM who underwent health examinations during 2007-2012 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0838-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423842PMC

Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.

Cardiovasc Diabetol 2019 03 18;18(1):35. Epub 2019 Mar 18.

Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France.

Background: This pathophysiological study addressed the hypothesis that soluble epoxide hydrolase (sEH), which metabolizes the vasodilator and anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs), contributes to conduit artery endothelial dysfunction in type 2 diabetes.

Methods And Results: Radial artery endothelium-dependent flow-mediated dilatation in response to hand skin heating was reduced in essential hypertensive patients (n = 9) and type 2 diabetic subjects with (n = 19) or without hypertension (n = 10) compared to healthy subjects (n = 36), taking into consideration cardiovascular risk factors, flow stimulus and endothelium-independent dilatation to glyceryl trinitrate. Diabetic patients but not non-diabetic hypertensive subjects displayed elevated whole blood reactive oxygen species levels and loss of NO release during heating, assessed by measuring local plasma nitrite variation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0843-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423843PMC
March 2019
4.015 Impact Factor

Effects of combined training with different intensities on vascular health in patients with type 2 diabetes: a 1-year randomized controlled trial.

Cardiovasc Diabetol 2019 03 18;18(1):34. Epub 2019 Mar 18.

Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, 1499-002, Cruz-Quebrada, Portugal.

Background: Exercise, when performed on a regular basis, is a well-accepted strategy to improve vascular function in patients with type 2 diabetes. However, the exercise intensity that yields maximal adaptations on structural and functional indices in patients with type 2 diabetes remains uncertain. Our objective was to analyze the impact of a 1-year randomized controlled trial of combined high-intensity interval training (HIIT) with resistance training (RT) vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0840-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423850PMC

Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.

Cardiovasc Diabetol 2019 03 16;18(1):33. Epub 2019 Mar 16.

Institut für Epidemiologie und medizinische Biometrie, ZIBMT; Universität Ulm, Ulm, Germany.

Background: To evaluate the characteristics of type 2 diabetes (T2DM) patients with or without chronic kidney disease (CKD) in Germany.

Methods: Using combined DPV/DIVE registry data, the analysis included patients with T2DM at least ≥ 18 years old who had an estimated glomerular filtration rate (eGFR) value available. CKD was defined as an eGFR < 60 mL/min/1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0837-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420726PMC
March 2019
6 Reads

Type 2 diabetes mellitus increases long-term mortality risk after isolated surgical aortic valve replacement.

Cardiovasc Diabetol 2019 03 15;18(1):31. Epub 2019 Mar 15.

Department of Cardiac Surgery, Tel Aviv University, Tel Aviv, Israel.

Background: Diabetes mellitus (DM) adversely affects morbidity and mortality for major atherosclerosis-related cardiovascular diseases and is associated with increased risk for the development of aortic stenosis. Clinical data regarding the impact of DM on outcomes of patients undergoing aortic valve replacement (AVR) have revealed inconsistent results. The aim of the current study was to investigate and compare the impact of type 2 DM on short-, intermediate- and long-term mortality between DM and non-DM patients who undergo isolated AVR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0836-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419403PMC

Retraction Note: Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report.

Cardiovasc Diabetol 2019 Mar 16;18(1):32. Epub 2019 Mar 16.

Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 463-707, South Korea.

The authors have retracted this article [1] because they have identified serious errors in their data analysis which change the conclusions of their study. All authors agree with this retraction. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0841-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420735PMC
March 2019
5 Reads

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.

Cardiovasc Diabetol 2019 03 11;18(1):28. Epub 2019 Mar 11.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.

Background: To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2 diabetes from a population-based cohort.

Methods: From a nationwide cohort in Korea (2008-2013), 23,674 patients with type 2 diabetes treated with DPP4i plus metformin or SU plus metformin were selected and matched by propensity score. Composite cardiocerebrovascular events including incident ischemic heart disease (IHD), ischemic stroke (IS), hospitalization for heart failure (HHF), and cardiocerebrovascular death, as well as renal events including incident end-stage renal disease or initiation of renal-replacement therapy were assessed by Cox proportional-hazards models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0835-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410523PMC
March 2019
1 Read

Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus.

Cardiovasc Diabetol 2019 03 11;18(1):29. Epub 2019 Mar 11.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 135-710, Republic of Korea.

Background: Cardiovascular autonomic neuropathy (CAN) is a major cause of morbidity and mortality in diabetes patients. Although several risk factors for CAN progression have been established, whether CAN is reversible remains unclear and the clinical factors associated with CAN recovery have not been identified. This study aimed to determine clinical factors related to CAN recovery. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0830-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410519PMC
March 2019
7 Reads

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis.

Cardiovasc Diabetol 2019 03 11;18(1):27. Epub 2019 Mar 11.

EA3920, University of Franche-Comte, 25000, Besancon, France.

Background: Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation.

Methods: A post hoc analysis of patients from our center included in the FRANCE and FRANCE-2 registries was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0831-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410509PMC
March 2019
1 Read

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.

Cardiovasc Diabetol 2019 03 11;18(1):30. Epub 2019 Mar 11.

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.

The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25-26 October 2018. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CARMELINA, DECLARE-TIMI 58 and Harmony Outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0822-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410488PMC

Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.

Cardiovasc Diabetol 2019 03 9;18(1):25. Epub 2019 Mar 9.

Isala Klinieken, Isala Hartcentrum, Dokter van Heesweg 2, 8025 AB, Zwolle, The Netherlands.

Background: Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) remains challenging even with modern drug-eluting stents (DES) due to high rates of repeat revascularization. Everolimus-eluting bioresorbable scaffolds (EE-BRS) might allow for repeat intervention prolonging the time interval of percutaneous treatment options.

Methods: The ABSORB DM Benelux Study is a dedicated prospective, international study to evaluate the midterm safety and efficacy of EE-BRS in DM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0827-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408833PMC

Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation.

Cardiovasc Diabetol 2019 03 9;18(1):26. Epub 2019 Mar 9.

Department of Medical Research, Bærum Hospital Vestre Viken Hospital Trust, Gjettum, PB 800, 3004, Drammen, Norway.

Aims: The prevalence of asymptomatic coronary artery disease (CAD) in type 2 diabetes (T2D) is unclear. We investigated the extent and prevalence of asymptomatic CAD in T2D patients by utilizing invasive coronary angiography (ICA) and intravascular ultrasound (IVUS), and whether CAD progression, evaluated by ICA, could be modulated with a multi-intervention to reduce cardiovascular (CV) risk.

Methods: Fifty-six T2D patients with ≥ 1 additional CV risk factor participated in a 2 year randomized controlled study comparing hospital-based multi-intervention (multi, n = 30) versus standard care (stand, n = 26), with a pre-planned follow-up at year seven. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0832-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408758PMC
March 2019
1 Read

Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study.

Cardiovasc Diabetol 2019 03 4;18(1):24. Epub 2019 Mar 4.

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138, Naples, Italy.

Background: In patients with Normal Glucose Tolerance (NGT) some causes of ischemic heart disease (IHD) were not completely investigated. The role both of metabolic milieu and adipokines in IHD progression was not fully investigated. Our aim was to assess the link between adipokines plasma levels, insulin resistance (IR) and IHD in NGT patients undergoing Percutaneous Coronary Intervention (PCI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0826-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399947PMC
March 2019
1 Read

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Cardiovasc Diabetol 2019 03 1;18(1):23. Epub 2019 Mar 1.

Cardiology Division, Pontifical Catholic University of Campinas Medicine School, Rua Engenheiro Carlos Stevenson 560, Campinas, Sao Paulo, 13092-132, Brazil.

Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0825-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396451PMC

Potential relation between soluble growth differentiation factor-15 and testosterone deficiency in male patients with coronary artery disease.

Cardiovasc Diabetol 2019 02 28;18(1):21. Epub 2019 Feb 28.

Dept of Clinical Laboratory, Wuhan Univ, Renmin Hospital, Jiefang Road 238, Wuhan, 430060, Hubei, China.

Background: There is a mutual interaction between inflammation and endocrine disorders in the development of coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is associated with CAD, and the effects of testosterone on CAD as reported in literature have been considered as anti-atherosclerotic. The present study aimed to examine the possible association between serum GDF-15 and testosterone in male CAD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0823-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394066PMC
February 2019
1 Read
4.015 Impact Factor

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.

Cardiovasc Diabetol 2019 02 28;18(1):20. Epub 2019 Feb 28.

Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0828-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393994PMC
February 2019
9 Reads

Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease.

Cardiovasc Diabetol 2019 02 28;18(1):22. Epub 2019 Feb 28.

Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.

Background: Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes. The timing, relative to disease onset, and degree of glycemic control that reduces the risk of adverse cardiovascular events remains uncertain. Coronary microvascular dysfunction is prevalent in patients with type 2 diabetes mellitus and is linked to adverse cardiovascular events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0833-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393964PMC
February 2019

Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.

Cardiovasc Diabetol 2019 02 28;18(1):19. Epub 2019 Feb 28.

Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

In Japan, the choice of anti-diabetic medication is officially recommended according to the patient's glycemic condition and disease phenotype, unlike most other regions where metformin is recommended as the first-line medication. There has been an increase in the number of available glucose-lowering agents, making it necessary to select these agents based on ever-improving evidence obtained from clinical trials. For the dipeptidyl peptidase-4 inhibitor class of drugs, nine drugs are currently available on the market in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0834-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394044PMC
February 2019
1 Read

Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D.

Cardiovasc Diabetol 2019 02 25;18(1):18. Epub 2019 Feb 25.

Department of Cardiovascular and Dysmetabolic Diseases, IRCCS MultiMedica, Via Fantoli 16/15, 20138, Milan, Italy.

Background: Impaired glucose tolerance (IGT) is a risk factor for the development of diabetes and related complications that ensue. Early identification of at-risk individuals might be beneficial to reduce or delay the progression of diabetes and its related complications. Recently, microRNAs emerged as potential biomarkers of diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0824-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388471PMC
February 2019

sRAGE and early signs of cardiac target organ damage in mild hypertensives.

Cardiovasc Diabetol 2019 02 12;18(1):17. Epub 2019 Feb 12.

Interdepartimental Center for Research in Molecular Medicine (CIRMC), University of Pavia, Pavia, Italy.

Background: Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic vascular diseases. However, it is still unknown whether sRAGE reduction could be early metabolic change in the first stage of hypertension and initial hypertension-associated cardiac damage. We sought to determine the sRAGE values in otherwise healthy, untreated and recently diagnosed mild hypertensives and evaluate their association with blood pressure (BP) values, metabolic parameters, and with subclinical initial signs of cardiac target organ damage (TOD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0821-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371567PMC
February 2019

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice.

Cardiovasc Diabetol 2019 02 7;18(1):16. Epub 2019 Feb 7.

Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden.

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i's promote a general shift to fasting state metabolism characterized by reduced body weight and blood glucose, increase in glucagon/insulin ratio and modest increase in blood ketone levels. Therefore, we investigated the connection between metabolic changes and cardiovascular function in the ob/ob mice; a rodent model of early diabetes with specific focus on coronary microvascular function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0820-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366096PMC
February 2019
7 Reads

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.

Cardiovasc Diabetol 2019 02 2;18(1):15. Epub 2019 Feb 2.

NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin, 300070, China.

Background: Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-independent manner. The aim of this study was to investigate the effect of empagliflozin on myocardium injury and the potential mechanism in type 2 diabetic KK-Ay mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0816-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359811PMC
February 2019
2 Reads

Comparative effects of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on carotid artery intima-media thickness progression: a network meta-analysis.

Cardiovasc Diabetol 2019 01 30;18(1):14. Epub 2019 Jan 30.

Department of Cardiothoracic Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.

Background: Carotid artery intima-media thickness (cIMT) progression is a surrogate marker of atherosclerosis with a high predictive value for future CVD risk. This study evaluates the comparative efficacies of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on cIMT progression.

Methods: We conducted a network meta-analysis (NMA) to evaluate the relative efficacies of several drug classes in modifying cIMT progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0817-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352423PMC
January 2019
3 Reads
4.015 Impact Factor

Early dysregulation of cardiac-specific microRNA-208a is linked to maladaptive cardiac remodelling in diabetic myocardium.

Cardiovasc Diabetol 2019 01 29;18(1):13. Epub 2019 Jan 29.

Department of Physiology-HeartOtago, Otago School of Medical Sciences, University of Otago, 270, Great King Street, Dunedin, 9010, New Zealand.

Background: The diabetic heart undergoes remodelling contributing to an increased incidence of heart failure in individuals with diabetes at a later stage. The molecular regulators that drive this process in the diabetic heart are still unknown.

Methods: Real-time (RT) PCR analysis was performed to determine the expression of cardiac specific microRNA-208a in right atrial appendage (RAA) and left ventricular (LV) biopsy tissues collected from diabetic and non-diabetic patients undergoing coronary artery bypass graft surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0814-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352455PMC
January 2019
2 Reads

Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.

Cardiovasc Diabetol 2019 01 28;18(1):11. Epub 2019 Jan 28.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotlic Disease, Clinical Centre for Coronary Heart Disease, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.

Background: Increasing evidence has suggested that the presence of remnant lipoproteins is a significant risk factor for atherosclerosis. Remnant lipoproteins are lipoproteins that are rich in triglycerides (TGs), and the main components include very-low-density lipoprotein (VLDL) in the fasting state. Diabetic patients often have hypertriglyceridemia with elevated levels of VLDL cholesterol but normal levels of low-density lipoprotein cholesterol (LDL-C). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0819-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348605PMC
January 2019
12 Reads

Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation.

Cardiovasc Diabetol 2019 01 28;18(1):12. Epub 2019 Jan 28.

Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, 830-0011, Japan.

Atrial fibrillation (AF) is one of the most common arrhythmias in elderly people. The risk of thromboembolic stroke is increased in AF patients, especially those with diabetes. Anticoagulant therapy, such as warfarin and non-vitamin K oral anticoagulants (NOACs), is recommended for diabetic patients with AF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0818-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348611PMC
January 2019

PDM-ProValue meets cardiovascular outcome trials in diabetes.

Cardiovasc Diabetol 2019 01 28;18(1):10. Epub 2019 Jan 28.

Forschergruppe Diabetes e.V., Muenchen-Neuherberg, Germany.

Novel studies have increased our knowledge regarding optimal treatment options in diabetes. Key studies that have broadened our knowledge about optimal treatment options in diabetes in recent years are cardiovascular outcome trials (CVOTs) and studies investigating aspects of digitalisation and monitoring of glucose (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0815-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348620PMC
January 2019

Developmental trajectories of body mass index from childhood into late adolescence and subsequent late adolescence-young adulthood cardiometabolic risk markers.

Cardiovasc Diabetol 2019 01 19;18(1). Epub 2019 Jan 19.

Nutritional Epidemiology, DONALD Study, Department of Nutrition and Food Sciences, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.

Background: Reports on body mass index (BMI) trajectories from childhood into late adolescence, their determinants, and subsequent cardiometabolic risk markers, particularly among European populations have been few. Moreover, sex-specific investigation is necessary considering the sex difference in BMI, and the sex-specific association between BMI and some cardiometabolic risk markers.

Methods: Using a sample from the DOrtmund Nutritional and Anthropometric Longitudinally Designed study, we explored sex-specific trajectories of the BMI standard deviation score (SDS) from 4 to 18 years of age in 354 males and 335 females by latent (class) growth models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0813-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339359PMC
January 2019
5 Reads

MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα.

Cardiovasc Diabetol 2019 01 11;18(1). Epub 2019 Jan 11.

Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Background: Metabolic abnormalities have been implicated as a causal event in diabetic cardiomyopathy (DCM). However, the mechanisms underlying cardiac metabolic disorder in DCM were not fully understood.

Results: Db/db mice, palmitate treated H9c2 cells and primary neonatal rat cardiomyocytes were employed in the current study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0811-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329097PMC
January 2019
5 Reads

Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach.

Cardiovasc Diabetol 2019 01 11;18(1). Epub 2019 Jan 11.

Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, People's Republic of China.

Background: Serum haptoglobin (Hp) has been closely associated with cardio-cerebrovascular diseases. We investigated a metabolic profile associated with circulating Hp and carotid arterial functions via a targeted metabolomics approach to provide insight into potential mechanisms.

Methods: A total of 240 participants, including 120 patients with type 2 diabetes mellitus (T2DM) and 120 non-diabetes mellitus (non-DM) subjects were recruited in this study. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0808-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329046PMC
January 2019
10 Reads

Improved outcome of patients with diabetes mellitus with good glycemic control in the cardiac intensive care unit: a retrospective study.

Cardiovasc Diabetol 2019 01 11;18(1). Epub 2019 Jan 11.

Diabetes Unit, Wolfson Medical Center, Holon, Israel.

Background: Diabetes mellitus (DM) is a prevalent metabolic disease characterized by chronic hyperglycemia. A primary burden of DM is related to its long-term complications, which have been shown to impact the course of hospitalization and to influence patients' outcome.

Aim: To assess the role of in-hospital glucose control on length of stay, 30-days and 1-year mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0810-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329158PMC
January 2019
4 Reads

Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects.

Cardiovasc Diabetol 2019 01 11;18(1). Epub 2019 Jan 11.

U.O.C. Clinica Medica e Malattie Vascolari, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo F. Vito 1, 00168, Rome, Italy.

Background: Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell types and circulating in blood. Higher circulating sortilin concentration has been found in patients with coronary atherosclerosis compared to control subjects. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0805-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329108PMC
January 2019
14 Reads

Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible.

Cardiovasc Diabetol 2019 01 11;18(1). Epub 2019 Jan 11.

Division of Cardiology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0812-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329062PMC
January 2019
1 Read

Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study.

Cardiovasc Diabetol 2019 01 10;18(1). Epub 2019 Jan 10.

Department of Internal Medicine, School of Medicine, University Hospital Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rua Rodolpho Rocco, 255, Cidade Universitária, Rio de Janeiro, CEP 21941-913, Brazil.

Background: The prognostic importance of carotid atherosclerosis in individuals with diabetes is unsettled. We aimed to evaluate the relationships between parameters of carotid atherosclerosis and the future occurrence of micro- and cardiovascular complications in individuals with type 2 diabetes.

Methods: Ultrasonographic parameters of carotid atherosclerosis, intima-media thickness (CIMT) and plaques, were measured at baseline in 478 participants who were followed-up for a median of 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0809-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327523PMC
January 2019
2 Reads

Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis.

Cardiovasc Diabetol 2019 01 10;18(1). Epub 2019 Jan 10.

Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Background: Epicardial fat tissue (EFT) is the visceral fat distributed along the coronary arteries between the pericardium and the myocardium. Increases in EFT are closely related to the occurrence of diabetes mellitus (DM) and cardiovascular disease. To further understand the link between EFT and DM, we conducted a meta-analysis of the relevant literature. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0807-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327515PMC
January 2019
10 Reads

Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction.

Cardiovasc Diabetol 2019 01 9;18(1). Epub 2019 Jan 9.

Cardiovascular Research Centre, 423 Heritage Medical Research Centre, University of Alberta, Edmonton, AB, T6G 2S2, Canada.

Background: In heart failure the myocardium becomes insulin resistant which negatively influences cardiac energy metabolism and function, while increasing cardiac insulin signalling improves cardiac function and prevents adverse remodelling in the failing heart. Glucagon's action on cardiac glucose and lipid homeostasis counteract that of insulin's action. We hypothesised that pharmacological antagonism of myocardial glucagon action, using a human monoclonal antibody (mAb A) against glucagon receptor (GCGR), a G-protein coupled receptor, will enhance insulin sensitivity and improve cardiac energy metabolism and function post myocardial infarction (MI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0806-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325856PMC
January 2019
1 Read